A 52-week, multicenter, randomized, double-blind, placebo controlled, parallel-group, group sequential, Phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 65 years with sickle-cell disease (LIBRA)
2026-09-14
عنوان الدراسة
A 52-week, multicenter, randomized, double-blind, placebo controlled, parallel-group, group sequential, Phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 65 years with sickle-cell disease (LIBRA)
داعم الدراسة
Sanofi
دواء الدراسة
Rilzabrutinib (SAR444671)
رقم بروتوكول الدراسة
EFC17872
حالة الدراسة
Ongoing
موقع الدراسة
1.King Faisal Specialist Hospital and Research Center - Riyadh 2.Prince Mohammed bin Nasser Hospital - Jazan
مرحلة الدراسة
3
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.